Clinical trial NCT01652911: A Phase I/II Study of the Safety and Efficacy of Sernova's Cell PouchTM for Therapeutic Islet Transplantation
Official title: A Phase I/II Study of the Safety and Efficacy of Sernova's Cell PouchTM for Therapeutic Islet Transplantation
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
PHASE2
Conditions: Type I Diabetes
Keywords: Islet Transplantation
Cell Pouch
Lead sponsor: University of Alberta
Sponsor class: OTHER
Collaborators: name: Sernova Corp
First posted: 2012-07-30
Enrollment: 3
Sex: ALL
Minimum age (years): 18
Maximum age (years): 68
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is an open-label, single arm, non-randomized safety and efficacy study, where participants with Type-1 diabetes will receive the Sernova Cell Pouch™ implanted in the subcutaneous site, two to approximately twelve weeks prior to transplantation of islets into the Cell Pouch™.

The primary objective of this study is to assess the safety of the Sernova Cell Pouch™ in adult participants with Type-1 diabetes receiving islet transplantation for the first time.

Secondary objectives are the following:

1. To determine the proportion of subjects implanted with the Cell Pouch™ and transplanted with islets into the Cell Pouch™ who achieve and maintain insulin independence after islet transplantation.
2. To obtain preliminary data on the efficacy of the Cell Pouch™ to maintain adequate immunological protection against both allo- and autoimmunity of islet transplant recipients.
3. To determine through retrospective analysis comparative metabolic function and engraftment efficiency using patients undergoing standard intraportal islet transplantation under the current alemtuzumab standard of care protocol.


Eligibility criteria: Inclusion Criteria:

To be eligible the participant must have had T1DM for more than 5 years, complicated by at least 1 of the following situations that persist despite intensive insulin management efforts:

1. Reduced awareness of hypoglycemia, as defined by the absence of adequate autonomic symptoms at plasma glucose levels \< 3.0 mmol/L, indicated by, 2 or more episodes of severe hypoglycemia requiring third party assistance within 12 months, a Clarke score ≥4, HYPO score ≥1,000, lability index (LI) ≥400 or combined Hypo/LI \>400/300
2. Metabolic instability, characterized by erratic blood glucose levels that interfere with daily activities and or 2 or more hospital visits for diabetic ketoacidosis over the last 12 months.

Participants must be capable of understanding the purpose and risks of the study and must sign a statement of informed consent.

Exclusion Criteria:

1. Severe co-existing cardiac disease, characterized by any one of these conditions: (a) recent myocardial infarction (within past 6 months); (b) left ventricular ejection fraction \<30%; or (c) evidence of ischemia on functional cardiac exam.
2. Active alcohol or substance abuse, to include cigarette smoking (must be abstinent for 6 months prior to transplant).
3. Psychiatric disorder making the subject not a suitable candidate for transplantation, (e.g., schizophrenia, bipolar disorder, or major depression that is unstable or uncontrolled on current medication).
4. History of non-adherence to prescribed regimens.
5. Active infection including Hepatitis C, Hepatitis B, HIV, TB (subjects with a positive PPD performed within one year of enrollment, and no history of adequate chemoprophylaxis).
6. Any history of or current malignancies except squamous or basal skin cancer.
7. BMI \> 35 kg/m2 at screening visit.
8. Age less than 18 or greater than 68 years.
9. Measured glomerular filtration rate (GFR) \<60 mL/min/1.73 m2.
10. Presence or history of macroalbuminuria (\>300 mg/g creatinine).
11. Clinical suspicion of nephritic (hematuria, active urinary sediment) or rapidly progressing renal impairment (e.g. Increase in serum creatinine of 25% within the last 3-6 months).
12. Baseline Hb \< 105g/L in women, or \< 120 g/L in men.
13. Baseline screening liver function tests outside of normal range, with the exception of uncomplicated Gilbert's Syndrome. An initial LFT panel with any values \>1.5 times the upper limit of normal (ULN) will exclude a patient without a re-test; a re test for any values between ULN and 1.5 times ULN should be made, and if the values remain elevated above normal limits, the patient will be excluded.
14. Untreated proliferative retinopathy.
15. Positive pregnancy test, intent for future pregnancy or male subjects' intent to procreate, failure to follow effective contraceptive measures, or presently breast feeding.
16. Previous transplant or evidence of significant sensitization on PRA (at the discretion of the investigator).
17. Insulin requirement \>1.0 U/kg/day
18. HbA1C \>12%.
19. Uncontrolled hyperlipidemia \[fasting LDL cholesterol \> 3.4 mmol/L, treated or untreated; and/or fasting triglycerides \> 2.3 mmol/L\].
20. Under treatment for a medical condition requiring chronic use of steroids.
21. Use of coumadin or other anticoagulant therapy (except aspirin) or subject with PT INR \> 1.5.
22. Untreated Celiac disease.
23. Patients with Graves disease will be excluded unless previously adequately treated with radioiodine ablative therapy.
24. Any medical condition that, in the opinion of the clinical investigator, will interfere with the safe participation in the trial.

Primary outcomes:
measure: To assess the safety of the Sernova Cell Pouch™ in adult participants with Type-1 diabetes receiving islet transplantation for the first time.
timeFrame: 3 years post-initial Cell Pouch™ implant.
Secondary outcomes:
measure: To determine the proportion of subjects implanted with the Cell Pouch™ and transplanted with islets into the Cell Pouch™ who achieve insulin independence after islet transplantation.
timeFrame: 3 years post-initial Cell Pouch™ implant.
measure: To obtain preliminary data on the efficacy of the Cell Pouch™.
timeFrame: 3 years post-initial CellPouch™
Other outcomes:
Locations:
city: Edmonton
country: Canada
facility: University of Alberta - Clinical Islet Transplant Program
state: Alberta
Study officials:
affiliation: University of Alberta
name: James Shapiro, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: